Mayo Clinic Laboratory and Pathology Research Roundup: Sept. 25

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.


Featured Abstract

Rates of Hippocampal Atrophy and Presence of Post-Mortem TDP-43 in Patients with Alzheimer's Disease: A Longitudinal Retrospective Study

Post-mortem studies have not identified an association between β-amyloid or tau and rates of hippocampal atrophy in patients with Alzheimer's disease. TAR DNA binding protein 43 (TDP-43) is another protein linked to Alzheimer's disease. Mayo Clinic researchers aimed to investigate whether hippocampal TDP-43 is associated with increased rates of hippocampal atrophy. In this longitudinal retrospective study, researchers analyzed post-mortem brain tissue of all individuals with an Alzheimer's disease spectrum pathological diagnosis who had antemortem head MRI scans between Jan 1, 1999, and Dec 31, 2012. Based on the results, TDP-43 should be considered as a potential factor related to increased rates of hippocampal atrophy in patients with Alzheimer's disease. Given the importance of hippocampal atrophy in Alzheimer's disease, it is imperative that techniques are developed for detection of TDP-43 in vivo. The review was published in The Lancet. Neurology.


Published to PubMed This Week

kschrib

Kelley Schreiber

Kelley Schreiber is a Marketing Channel Manager at Mayo Medical Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her new kitten, and exploring new foods.